Sharon Winton, the CEO and director of Lymphoma Australia, said, “Patients living with DLBCL deserve options at every stage of their treatment journey. The availability of another treatment option for patients who have already undergone two or more lines of therapy acknowledges this need and is welcomed by the community.” …
Stakeholders welcome the PBS listing of AbbVie's blood cancer therapy
April 28, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
ARCS evolves into LifeSciences Australia as part of wider strategic change
June 11, 2026 - - Latest News -
Sigma confirms interest in the acquisition of UK pharmacy chain Boots
June 10, 2026 - - Latest News -
Island secures US partnership to advance Galidesivir dose study for Marburg
June 10, 2026 - - Australian Biotech -
Cartherics secures Japanese patent to bolster cell therapy push
June 10, 2026 - - Australian Biotech -
GSK to buy Nuvalent in a major move to acquire rights to late stage lung cancer candidates
June 10, 2026 - - Latest News -
Australian company secures US fast track for CAR-T in blood cancers
June 10, 2026 - - Latest News -
Industry campaign highlights MFN risk to US jobs and the broader economy
June 10, 2026 - - Latest News